Sanofi signs on to sell Vivus ED med in emerging markets; GSK's quadrivalent flu vaccine impresses in NEJM study;

@FiercePharma: India's Lupin already launched its copies of Eli Lilly's $5B antidepressant, Cymbalta, in U.S. Half-dozen companies got FDA nod. Poor Lilly. | Follow @FiercePharma

@EricPFierce: Merck KGaA's Allergopharma unit building a €40M plant near Hamburg that will make allergy meds for China. Release | Follow @EricPFierce

@CarlyHFierce: Here come the Cymbalta copies. FDA approves generics from Teva, Sun, Dr. Reddy's, Lupin and others. Release | Follow @CarlyHFierce

> Vivus ($VVUS) has found another marketing partner for its erectile dysfunction drug Stendra: Sanofi ($SNY), which will promote the drug in several emerging markets, including Russia and Turkey. Release

> GlaxoSmithKline's ($GSK) FluLaval quadrivalent flu vaccine cut flu cases in small children by 55% and slashed the risk of moderate-to-serious illness by 73%, a New England Journal of Medicine study found. Release | Report

> Roche's ($RHHBY) cancer fighter Herceptin (trastuzumab) is poised for a big boost in China in HER2-positive gastric cancer, Decision Resources found, with one key reimbursement decision on its way. Report

> Novartis ($NVS) said its myelofibrosis treatment Jakavi (ruxolitinib) helped study patients live longer than those treated with placebo or conventional therapy. Report

> GlaxoSmithKline said stockists and retailers in India have resumed purchasing its products after a pricing-related protest that began in September. Report

> Warner Chilcott inked a patent settlement with Zydus Pharmaceuticals that will allow the India-based generics maker to launch a generic version of the colitis treatment Asacol HD beginning Nov. 15, 2015. Report

> The German pharma wholesaler Celesio said its board had recommended shareholder approval for an $8.3 billion takeover by rival McKesson ($MCK). Report

Medical Device News

@FierceMedDev: Avinger draws new financing to back testing of light-enhanced PAD catheter. Article | Follow @FierceMedDev

@MarkHFierce: St. Jude Medical won a CE mark for a larger size of its Portico heart valve, adding to a now-crowded competition. More | Follow @MarkHFierce

@MichaelGFierce: AdvaMed, MDMA commend congressional budget deal as vote approaches. Story | Follow @MichaelGFierce

@GalenMoore: Senesco Announces up to $25.2 Million Equity Financing. Release | Follow @GalenMoore

> Boston Scientific's Watchman stroke-fighting device wins overwhelming FDA panel support. Piece

> T2 brings on 2 Hologic vets as work continues on Candida assay ramp-up. News

Biotech News

@FierceBiotech: In January, Levin dumped Teva's immunotherapy program. Now, checkpoint receptor drugs are all the rage. More | Follow @FierceBiotech

@JohnCFierce: Galderma Labs axing staff in U.S. shakeup after president exits (gee, the rumors were true). News | Follow @JohnCFierce

@DamianFierce: Imagine being the Novartis worker who picked up Retrophin's call. "Hey, so, remember Syntocinon?" | Follow @DamianFierce

@EmilyMFierce: Congressional budget deal would restore NIH sequester cuts. Coverage | Follow @EmilyMFierce

> FDA panel throws dirt on Bristol-Myers' orphan drug metreleptin. Story

> ImmunoCellular tanks after cancer vaccine flops on key endpoint in PhII. Article

> Roche signs Prothena for up to $600M in Parkinson's drug development deal. More

Vaccines News

> GSK shares data from pivotal PhIII trial of quadrivalent flu vaccine. Story

> Novartis awaits pivotal Bexsero decisions in Canada and Europe. Piece

> Genocea begins a PhI trial of its rival to Pfizer's Prevnar. News

> AstraZeneca eyes 2014 EU launch for 4-in-1 flu vaccine after winning approval. More

> Pentagon tasks Pfizer with radically rethinking vaccine development. Article

> Lundbeck teams with Otsuka on Alzheimer's vaccine development. Item

Pharma Manufacturing News

> ScinoPharma's $113 million China API plant ready to go. News

> Merck KGaA targets China with a planned, €40M allergy plant. More

> FDA stationing 10 new drug inspectors in China. Story

> GSK's new manufacturing investments in the U.K. now pass $1 billion. Article

> Cardinal, CVS JV creates more upheaval in U.S. drug supply chain. Piece

> FDA warns NJ lotion maker: Your water does not meet specs. Item

And Finally ... Cancer deaths around the world rose to 8.2 million last year, including a disturbing rise in deaths from breast cancer. Report

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.